Neurogene Inc. (NGNE)

Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $316.61 million. The enterprise value is $61.41 million.

Market Cap	316.61M
Enterprise Value	61.41M

Important Dates

The last earnings date was Thursday, November 13, 2025, after market close.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 15.49 million shares outstanding. The number of shares has increased by 60.75% in one year.

Current Share Class	15.49M
Shares Outstanding	15.49M
Shares Change (YoY)	+60.75%
Shares Change (QoQ)	+0.54%
Owned by Insiders (%)	10.06%
Owned by Institutions (%)	48.28%
Float	6.00M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.14
P/TBV Ratio	1.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.39, with a Debt / Equity ratio of 0.04.

Current Ratio	18.39
Quick Ratio	18.10
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-16,218.50

Financial Efficiency

Return on equity (ROE) is -42.25% and return on invested capital (ROIC) is -28.53%.

Return on Equity (ROE)	-42.25%
Return on Assets (ROA)	-26.91%
Return on Invested Capital (ROIC)	-28.53%
Return on Capital Employed (ROCE)	-35.63%
Revenue Per Employee	n/a
Profits Per Employee	-$795,607
Employee Count	107
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.69% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+0.69%
50-Day Moving Average	25.51
200-Day Moving Average	19.61
Relative Strength Index (RSI)	35.49
Average Volume (20 Days)	257,238

Short Selling Information

The latest short interest is 2.84 million, so 18.36% of the outstanding shares have been sold short.

Short Interest	2.84M
Short Previous Month	2.86M
Short % of Shares Out	18.36%
Short % of Float	47.45%
Short Ratio (days to cover)	11.24

Income Statement

Revenue	n/a
Gross Profit	-69.72M
Operating Income	-97.31M
Pretax Income	-85.13M
Net Income	-85.13M
EBITDA	-94.21M
EBIT	-97.31M
Earnings Per Share (EPS)	-$4.12

Balance Sheet

The company has $265.41 million in cash and $10.21 million in debt, giving a net cash position of $255.20 million or $16.48 per share.

Cash & Cash Equivalents	265.41M
Total Debt	10.21M
Net Cash	255.20M
Net Cash Per Share	$16.48
Equity (Book Value)	265.54M
Book Value Per Share	17.97
Working Capital	255.81M

Cash Flow

In the last 12 months, operating cash flow was -$77.24 million and capital expenditures -$1.17 million, giving a free cash flow of -$78.41 million.

Operating Cash Flow	-77.24M
Capital Expenditures	-1.17M
Free Cash Flow	-78.41M
FCF Per Share	-$5.06

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-60.75%
Shareholder Yield	-60.75%
Earnings Yield	-26.89%
FCF Yield	-24.77%

Analyst Forecast

The average price target for Neurogene is $38.50, which is 88.36% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$38.50
Price Target Difference	88.36%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	132.79%
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurogene has an Altman Z-Score of 7.06 and a Piotroski F-Score of 2.

Altman Z-Score	7.06
Piotroski F-Score	2